-0.43 | -1.22%
QUESTCOR PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2013 has decreased when compared to the same period a year ago. Sales and net income have grown, and although the growth in revenues has outpaced the average competitor within the industry, the net income growth has not. QUESTCOR PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.26 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has decreased by 16.40% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
| Income Statement | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Net Sales ($mil) | 135.13 | 95.97 |
| EBITDA ($mil) | 60.34 | 57.63 |
| EBIT ($mil) | 59.27 | 57.34 |
| Net Income ($mil) | 39.06 | 38.54 |
| Balance Sheet | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Cash & Equiv. ($mil) | 153.42 | 223.66 |
| Total Assets ($mil) | 345.75 | 302.62 |
| Total Debt ($mil) | 17.74 | 0.0 |
| Equity ($mil) | 195.7 | 234.11 |
| Profitability | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Gross Profit Margin | 88.02 | 94.25 |
| EBITDA Margin | 44.65 | 60.04 |
| Operating Margin | 43.86 | 59.74 |
| Sales Turnover | 1.59 | 0.92 |
| Return on Assets | 57.32 | 35.32 |
| Return on Equity | 101.27 | 45.66 |
| Debt | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Current Ratio | 2.56 | 4.28 |
| Debt/Capital | 0.08 | 0.0 |
| Interest Expense | 0.0 | 0.0 |
| Interest Coverage | 0.0 | 0.0 |
| Share Data | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Shares outstanding (mil) | 59.55 | 63.03 |
| Div / share | 0.0 | 0.0 |
| EPS | 0.65 | 0.58 |
| Book value / share | 3.29 | 3.71 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 2087254.0 | 1572012.0 |
BUY. The current P/E ratio indicates a significant discount compared to an average of 24.42 for the Pharmaceuticals industry and a discount compared to the S&P 500 average of 19.08. For additional comparison, its price-to-book ratio of 11.22 indicates a significant premium versus the S&P 500 average of 2.44 and a significant premium versus the industry average of 6.58. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. The valuation analysis reveals that, QUESTCOR PHARMACEUTICALS INC seems to be trading at a discount to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QCOR 11.38 | Peers 24.42 | QCOR 9.73 | Peers 18.01 | |||||||||||||||||||||
|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations. QCOR is trading at a significant discount to its peers. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. QCOR is trading at a significant discount to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| QCOR 8.52 | Peers 15.97 | QCOR 0.44 | Peers 0.63 | |||||||||||||||||||||
|
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations. QCOR is trading at a significant discount to its peers. |
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. QCOR trades at a significant discount to its peers. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| QCOR 11.22 | Peers 6.58 | QCOR 100.00 | Peers -7.87 | |||||||||||||||||||||
|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. QCOR is trading at a significant premium to its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. QCOR is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| QCOR 4.00 | Peers 4.93 | QCOR 97.78 | Peers 13.67 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. QCOR is trading at a discount to its industry on this measurement. |
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share. QCOR has a sales growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
